Rabbit Polyclonal JAK2 Antibody

+ +

•  

   

     Western blot analysis of PLA2G1B Antibody (C-term) (Cat. #P30573) in mouse spleen tissue lysates (35ug/lane). PLA2G1B (arrow) was detected using the purified Pab.    

  
  

•  

   

     Western blot analysis of PLA2G1B (arrow) using rabbit polyclonal PLA2G1B Antibody (C-term) (Cat. #P30573). 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected (Lane 2) with the PLA2G1B gene.    

  
  

•  

   

     PLA2G1B Antibody (C-term) (Cat. #P30573) flow cytometric analysis of 293 cells (right histogram) compared to a negative control cell (left histogram).FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.    

  
  

JAK2 (Janus kinase 2) is a cytoplasmic tyrosine kinase critical for signaling pathways of cytokine receptors, including erythropoietin, thrombopoietin, and granulocyte-colony stimulating factor. It plays a key role in hematopoiesis, immune regulation, and cell growth. The JAK2 V617F mutation, identified in 2005. causes constitutive activation of the kinase, leading to uncontrolled cell proliferation. This mutation is strongly associated with myeloproliferative neoplasms (MPNs), such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis.

Anti-JAK2 antibodies are tools used in research and diagnostics to detect JAK2 protein expression or specific mutations. In clinical settings, detecting JAK2 V617F via antibody-based assays (e.g., ELISA, immunohistochemistry) or molecular techniques aids in diagnosing MPNs and differentiating them from reactive conditions. Additionally, JAK2 antibodies are employed in studying signaling mechanisms, drug development, and monitoring therapeutic responses.

Therapeutic JAK inhibitors (e.g., ruxolitinib) target hyperactive JAK2 pathways, highlighting the protein's clinical relevance. However, wild-type JAK2 is essential for normal hematopoiesis, complicating targeted therapies. Research continues to explore isoform-specific antibodies and mutation-selective inhibitors to improve diagnostic accuracy and treatment outcomes while minimizing off-target effects.